Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 350

1.

Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma.

Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, DeMarini DJ, Gardner O, Crist W, Patel K.

Cancer Chemother Pharmacol. 2016 Apr;77(4):807-17. doi: 10.1007/s00280-016-2993-y. Epub 2016 Mar 3.

PMID:
26940938
2.

Improved overall survival in melanoma with combined dabrafenib and trametinib.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D.

N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.

3.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group.

N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.

4.
5.

Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.

Raney B, Stoner J, Anderson J, Andrassy R, Arndt C, Brown K, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Hayes-Jordan A; Soft-Tissue Sarcoma Committee of the Children's Oncology Group.

J Pediatr Surg. 2010 Nov;45(11):2160-8. doi: 10.1016/j.jpedsurg.2010.07.021.

6.

Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972-2005: A report from the Children's Oncology Group.

Raney B, Anderson J, Arndt C, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W; Soft-Tissue Sarcoma Committee of The Children's Oncology Group, Arcadia, CA.

Pediatr Blood Cancer. 2008 Sep;51(3):339-43. doi: 10.1002/pbc.21639.

7.

Surgical Principles for Children/Adolescents With Newly Diagnosed Rhabdomyosarcoma: A Report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Rodeberg DA, Paidas CN, Lobe TL, Brown K, Andrassy RJ, Crist WM, Wiener ES.

Sarcoma. 2002;6(4):111-22. doi: 10.1080/1357714021000066359. No abstract available.

8.

The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM.

Sarcoma. 2001;5(1):9-15. doi: 10.1080/13577140120048890.

9.

Feeding difficulties in children with CHARGE syndrome: prevalence, risk factors, and prognosis.

Dobbelsteyn C, Peacocke SD, Blake K, Crist W, Rashid M.

Dysphagia. 2008 Jun;23(2):127-35. Epub 2007 Nov 20.

PMID:
18027028
10.

Witnessing a metamorphosis of medicine at MU.

Crist WM.

Mo Med. 2007 Mar-Apr;104(2):108-10. No abstract available.

PMID:
17536435
11.

Vote YES on the Missouri stem cell research and cures initiative.

Atkinson B, Shapiro L, Crist W, Slocum P, Drees B, Willsie S, Neaves W.

Mo Med. 2006 Sep-Oct;103(5):498-9. No abstract available.

PMID:
17139703
12.

Funding for medicine at UMC would benefit all Missourians.

Crist WM, Hugh E, Stephenson SD.

Mo Med. 2006 Mar-Apr;103(2):138. No abstract available.

PMID:
16703711
13.
14.

Pediatric assessment scale for severe feeding problems: validity and reliability of a new scale for tube-fed children.

Crist W, Dobbelsteyn C, Brousseau AM, Napier-Phillips A.

Nutr Clin Pract. 2004 Aug;19(4):403-8.

PMID:
16215132
15.
16.

Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Sung L, Anderson JR, Donaldson SS, Spunt SL, Crist WM, Pappo AS; Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Eur J Cancer. 2004 Aug;40(12):1878-85.

PMID:
15288290
17.

Results of treatment of fifty-six patients with localized retroperitoneal and pelvic rhabdomyosarcoma: a report from The Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.

Raney RB, Stoner JA, Walterhouse DO, Andrassy RJ, Donaldson SS, Laurie F, Meyer WH, Qualman SJ, Crist WM; Intergroup Rhabdomyosarcoma Study-IV, 1991-1997.

Pediatr Blood Cancer. 2004 Jun;42(7):618-25.

PMID:
15127417
18.

Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W; Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Pediatr Blood Cancer. 2004 Jan;42(1):64-73.

PMID:
14752797
19.

Web-based decision support for clinical trial eligibility determination in an international clinical trials network.

Breitfeld PP, Ullrich F, Anderson J, Crist WM.

Control Clin Trials. 2003 Dec;24(6):702-10.

PMID:
14662275
20.

Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.

Blakely ML, Andrassy RJ, Raney RB, Anderson JR, Wiener ES, Rodeberg DA, Paidas CN, Lobe TE, Crist WM; Intergroup Rhabdomyosarcoma Studies I through IV.

J Pediatr Surg. 2003 Mar;38(3):347-53. Review.

PMID:
12632347

Supplemental Content

Loading ...
Support Center